American Journal of Medical and Clinical Sciences. 2022;
7(3):(69-142)
Rhabdomyosarcoma-Like and Non-Rhabdomyosarcoma-Like in Children: Assessment of Outcomes in Combination Cancer Therapy
Miłosz Jazdon, Dominika Kuc, Olga Radziejewska, Swati Singh, and Katarzyna Derwich
Abstract
Soft tissue sarcomas (STS) are rare malignant neoplasms, accounting for approximately
7-8% of childhood cancers. The 5-year survival rate varies from 15-90% depending on the
severity of the disease. The purpose of our study was to assess the therapeutic results
of patients who received combined treatment, according to CWS Protocols implemented
at the Department of Pediatric Oncology, Hematology and Transplantology (DPOHT) in
Poznan (2007: 2017). The study group consisted of 29 children, although the final analysis
of treatment outcomes was completed in 25 children, 18 (72%) boys and 7 (28%) girls.
Combined treatment according to the regimens of VAIA III, CEVAIA, O-TIE, radiotherapy and
surgery was applied. After first-line treatment, 17/25 (68%) patients achieved remission
and 7/25 (28%) died due to disease progression without achieving remission. One child
(4%) received palliative care with disease progression. In 3/17 (18%) children, the disease
relapsed. The pOS for the RMS-like group is 0.530 and the non-RMS-like group is 0.621. The
pEFS for the RMS-like group is 0.578 and the non-RMS group is 0.505. The 5-year survival
probability of RMS-like and non-RMS-like patients, despite intensive treatment, is lower
than other childhood cancers. In the study group, treatment failures were mainly due to
treatment resistance.
